Lupin

    LUPIN
    Pharma
    ₹1,928.90
    Price as of 25 Oct 2026, 10:28 pm IST

    Market cap ₹88,207 Cr

    P/E
    15.98
    Day range
    ₹1,892.90 – ₹1,929.90
    52-week range
    ₹1,892.90 – ₹2,529.50
    Volume
    7.02 L
    Open
    ₹1,922.00
    Prev close
    ₹1,922.00

    Latest results · Q1 FY27(consolidated)Revenue ₹8,277 Cr+32.0%Profit ₹1,417 Cr+16.0%Margin 17.1%YoY vs the same quarter last year

    No red flags in exchange filings: no rising pledge, promoter selling, surveillance or critical filing on record.

    LUPIN in NSE indices and F&O

    F&O margin for one lot of LUPIN (425 shares)

    Research profile

    Composite 70 / 100

    Factor percentiles

    Value73
    Quality79
    Momentum36
    Low volatility90

    Derived metrics

    Earn. yield
    6.3%
    Graham no.
    ₹1,199.93
    vs Graham
    -37.8%
    ROE ÷ P/B
    6.9%
    12-1 mom.
    +10.2%
    Return / vol
    -0.02
    Magic Formula
    #34
    Piotroski
    6/6
    FCF yield
    6.0%
    PEG
    0.18

    Appears in 17 scans

    Percentiles rank this stock against the other tracked stocks and change as they do. Scans describe where figures sit today. Hover a label for its definition. Not investment advice.

    Peer comparison

    All 67 in Pharma
    Largest Pharma companies tracked, with sector medians
    CompanyM-capP/EP/BROEROCEOPMD/ESales YoY
    Sun PharmaSUNPHARMA₹4.19 L Cr34.685.0214.8%21.0%29.0%0.06+10.5%
    Divi's LaboratoriesDIVISLAB₹2.38 L Cr81.2114.5216.2%22.0%41.0%0.00+27.8%
    Torrent PharmaTORNTPHARM₹1.72 L Cr76.439.3726.8%15.0%33.0%0.77+50.8%
    Zydus LifesciencesZYDUSLIFE₹1.13 L Cr25.174.2020.1%21.0%24.0%0.46+22.0%
    Apollo HospitalsAPOLLOHOSP₹1.11 L Cr53.1911.5422.6%17.0%16.0%0.90+20.6%
    CiplaCIPLA₹1.08 L Cr32.093.1211.8%15.0%17.0%0.02+2.3%
    Laurus LabsLAURUSLABS₹1.06 L Cr97.3820.0618.2%18.0%32.0%0.48+29.0%
    LupinLUPIN₹88,207 Cr15.983.9327.0%30.0%30.0%0.29+32.1%
    Sector median₹23,579 Cr41.615.6015.1%17.0%25.0%0.16+20.7%

    Sector as classified in the tracked universe; medians use every tracked Pharma company, and P/E only profitable ones. Tinted figures beat the median.

    Latest news

    Updated 2d ago

    Headlines about Lupin from the last two weeks in the financial press. Stories belong to their publishers; Parasram India does not endorse them.

    Key metrics

    P/E (TTM)
    14.8
    EPS (TTM)
    ₹127.94
    Price / Book
    3.93
    ROE (FY26)
    27.0%
    ROCE (latest year)
    30%
    Dividend yield
    0.93%

    Moving averages (NSE)

    20-day
    ₹1,992.66
    Price below
    50-day
    ₹2,089.79
    Price below
    200-day
    ₹2,246.94
    Price below

    Charts & trends

    From company filings. Amounts in ₹ crore.

    Revenue 3Y CAGR
    +18.9%
    Profit 3Y CAGR
    +128.6%
    Revenue YoY (Jun 2026)
    +32.1%
    Profit YoY (Jun 2026)
    +16.1%
    Operating margin
    30.0%
    Net margin
    17.1%

    Revenue, profit & margin - quarterly

    ₹ crore; a loss shows red. Operating margin below, same periods.

    0 Cr2.5K Cr5K Cr7.5K Cr10K Cr
    • Revenue
    • Net profit

    Operating margin

    Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Jun 20260%20%40%

    Who owns the company

    % of equity by quarter, latest Sept 2026

    Dec '24Mar '25Jun '25Sept '25Dec '25Mar '26Jun '26Sept '260%25%50%75%100%
    • Promoter
    • DII
    • FII
    • Public
    • Government

    Cash flows

    Where cash came from and went, by fiscal year (₹ crore)

    Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026-5K Cr0 Cr5K Cr10K Cr
    • Operating
    • Investing
    • Financing
    • Free cash flow

    Return on equity

    Net profit over shareholders' equity, by fiscal year

    FY17FY18FY19FY20FY21FY22FY23FY24FY25FY26-20%-10%0%10%20%30%15% screen

    Equity vs debt

    Shareholders' equity against borrowings (₹ crore); the ratio below, same years.

    0 Cr10K Cr20K Cr30K Cr
    • Equity
    • Debt

    Debt to equity

    Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 20260x0.5x1x

    Dividends per share

    ₹ by fiscal year of the ex-date; the latest year runs to date.

    FY18FY19FY20FY21FY22FY23FY24FY25FY26FY27₹0₹5₹10₹15₹20

    Financial statements

    ₹ Crore
    Quarterly results, oldest period first, figures in rupees crore
    Line itemSep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
    Sales5,0395,1974,9615,6005,6735,7685,6676,2687,0487,1687,4758,277
    Expenses4,1214,1593,9644,3594,3324,4124,3464,5414,7064,9064,9895,827
    Operating Profit9181,0389971,2411,3401,3561,3211,7272,3412,2622,4862,450
    OPM %18%20%20%22%24%24%23%28%33%32%33%30%
    Other Income402929684254577990-3129130
    Interest8174716871678992108115120110
    Depreciation248257457248257271393299317313447453
    Profit before tax6307364989931,0551,0718961,4162,0071,5221,9282,017
    Tax %21%16%26%19%19%20%13%14%26%22%24%30%
    Net Profit4956193688068598597821,2211,4851,1811,4691,417
    EPS in Rs₹10.76₹13.47₹7.89₹17.58₹18.69₹18.74₹16.92₹26.69₹32.36₹25.73₹31.94₹30.95

    From company filings, updated 24 Oct 2026. Consolidated figures where the company reports them. Information only, not investment advice.

    Working-capital cycle

    Debtor Days86

    -22 days since Mar 2021

    Inventory Days303

    +24 days since Mar 2021

    Days Payable208

    +71 days since Mar 2021

    Cash Conversion Cycle181

    -68 days since Mar 2021

    Working Capital Days28

    -6 days since Mar 2021

    Strengths, risks & growth

    Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai. Lupin develops and commercializes a wide range of branded and generic formulations, biotechnology products, and APIs in over 100 markets in the U.S., India, South Africa, and across the Asia Pacific (APAC), Latin America (LATAM), Europe, and Middle East regions.

    Strengths

    • Company has delivered good profit growth of 37.0% CAGR over last 5 years
    • Company has been maintaining a healthy dividend payout of 17.1%
    • Company's working capital requirements have reduced from 46.4 days to 28.0 days

    Risks

    None flagged by the checklist.

    Compounded Sales Growth

    10 Years
    +7%
    5 Years
    +13%
    3 Years
    +19%
    TTM
    +28%

    Compounded Profit Growth

    10 Years
    +10%
    5 Years
    +37%
    3 Years
    +140%
    TTM
    +61%

    Stock Price CAGR

    10 Years
    +3%
    5 Years
    +16%
    3 Years
    +19%
    1 Year
    0%

    Return on Equity

    10 Years
    +10%
    5 Years
    +13%
    3 Years
    +22%
    Last Year
    +29%

    Strengths and risks are a machine-generated checklist, not advice; growth is compounded annually over each period.

    Shareholding pattern

    Percentage of shares held by each category at each quarter end
    HolderDec 2025Mar 2026Jun 2026Sept 2026Change
    Promoter46.89%46.85%46.85%46.84%-0.01 pp
    FII21.50%21.70%22.42%23.28%+0.86 pp
    DII25.58%25.32%24.65%23.78%-0.87 pp
    Government0.00%0.00%0.00%0.00%0.00 pp
    Public6.04%6.13%6.08%6.08%0.00 pp

    Filed with NSE for Sept 2026: promoters 46.84%, public 53.16% · XBRL filing

    Analysts & fund holdings

    50%
    50% recommend buy
    34 analysts cover the stock
    Valuation vs Pharmaceuticals
    P/E16.0 vs 44.2
    Sector P/B5.54
    Beta0.78

    Who holds the shares, quarter by quarter

    Mutual funds 14.58% (-0.26 pp)
    Jun 25
    Sept 25
    Dec 25
    Mar 26
    Jun 26
    Sept 26
    • Promoters46.8%
    • Foreign institutions23.3%
    • Mutual funds14.6%
    • Insurance6.4%
    • Other domestic institutions2.8%
    • Retail5.0%
    • Others1.1%
    Mutual funds holding the most
    Fund% of company% of fund3-month change
    HDFC Balanced Advantage Fund1.29%1.13%-0.17 pp
    HDFC Flexi Cap Fund1.16%0.91%+0.08 pp
    HDFC Large Cap Fund1.04%2.51%-0.35 pp
    Mirae Asset Large & Midcap Fund0.89%1.87%-0.16 pp
    Mirae Asset Midcap Fund0.73%3.34%-0.08 pp

    Scorecard

    Performance
    Avg
    Valuation
    High
    Growth
    High
    Profitability
    High
    Entry point
    Good
    Red flags
    Low

    Analyst coverage, holdings and scorecard from market data; not a recommendation by Parasram India.

    Risk & trend

    From 275 daily sessions to 23 Oct 2026.

    Computed

    Risk

    Volatility (1Y)
    20.1%
    Downside volatility
    19.6%
    Worst 5% of days
    2.0%
    Average of that tail
    2.9%
    Max drawdown (1Y)
    23.6%
    Below its peak
    23.3%

    Against the market

    Beta vs Nifty 50
    0.56
    Correlation
    0.37
    Relative strength (3M)
    -14.2%
    ATR (14)
    2.1%

    Return

    Return 1M
    -9.7%
    Return 3M
    -19.5%
    Return 6M
    -16.4%
    Return 1Y
    -0.4%
    vs 200-day average
    -14.2%

    Momentum

    RSI (14)
    34.7
    MACD histogram
    1.21
    Stochastic %K
    26.0
    ADX (14)
    45.2
    +DI / −DI
    7.9 / 25.9
    Money flow index
    33.3

    Participation

    Delivery (20d avg)
    58.7%
    vs its 60-day baseline
    -0.5 pts
    Volume vs 20-day
    +0.1σ
    Close vs day's VWAP
    +0.8%
    52-week position
    4 / 100

    These describe what this stock's price has already done. They are not forecasts, signals or recommendations, and a dash means the figure was withheld for want of enough history rather than being zero.

    Financial quality

    From consolidated statements to 31 Mar 2026.

    Computed

    Piotroski F-Score

    6 of 6 tested

    • Return on assets positive — passed
    • Operating cash flow positive — not testableno cash flow statement for this period
    • Return on assets improving — passed
    • Cash flow exceeds profit — not testableneeds cash flow and profit against assets
    • Debt to assets falling — passed
    • Current ratio improving — passed
    • No new equity issued — not testableno share count is collected, and financing cash flow mixes equity with debt
    • Operating margin improving — passed
    • Asset turnover improving — passed
    Free cash flow
    ₹5,280 Cr
    FCF yield
    6.0%
    Cash conversion
    1.37
    Accruals ratio
    -0.052
    Net debt
    ₹2,448 Cr
    Net debt / equity
    0.11
    EV / sales
    3.03
    PEG
    0.18
    Capex intensity
    7.3%
    Revenue CAGR
    31.9%
    Profit CAGR
    87.7%

    Computed from filed statements, not filed themselves. A dash means an input was absent, and the score counts only the criteria that could actually be tested.

    Corporate actions

    • dividend
      ₹18.00

      Dividend - Rs 18 Per Share

      17 Jul 2026
      ex-date
    • dividend
      ₹12.00

      Dividend - Rs 12 Per Share

      25 Jul 2025
      ex-date
    • dividend
      ₹8.00

      Dividend - Rs 8 Per Share

      16 Jul 2024
      ex-date
    • dividend
      ₹4.00

      Dividend - Rs 4 Per Share

      14 Jul 2023
      ex-date
    • dividend
      ₹4.00

      Dividend - Rs 4 Per Share

      14 Jul 2022
      ex-date
    • dividend
      ₹6.50

      Dividend - Rs 6.50 Per Share

      27 Jul 2021
      ex-date
    • dividend
      ₹6.00

      Annual General Meeting/Dividend - Rs 6 Per Share

      3 Aug 2020
      ex-date
    • dividend
      ₹5.00

      Annual General Meeting/Dividend - Rs 5 Per Share

      29 Jul 2019
      ex-date
    • dividend
      ₹5.00

      Annual General Meeting/Dividend Rs 5/- Per Share

      30 Jul 2018
      ex-date
    • dividend
      ₹7.50

      Annual General Meeting/Dividend - Rs 7.50 Per Share

      24 Jul 2017
      ex-date
    • dividend
      ₹7.50

      Annual General Meeting/ Dividend -Rs 7.50/- Per Share

      25 Jul 2016
      ex-date
    • dividend
      ₹7.50

      Annual General Meeting/ Dividend - Rs 7.50/- Per Share

      14 Jul 2015
      ex-date
    • dividend
      ₹3.00

      Annual General Meeting / Final Dividend - Rs 3/- Per Share

      21 Jul 2014
      ex-date
    • dividend
      ₹3.00

      Interim Dividend - Rs 3/- Per Share

      13 Feb 2014
      ex-date
    • dividend
      ₹4.00

      Annual General Meeting / Dividend - Rs 4/- Per Share

      29 Jul 2013
      ex-date
    • dividend
      ₹3.20

      Annual General Meeting And Dividend Rs.3.20 Per Share

      13 Jul 2012
      ex-date
    • dividend
      ₹3.00

      Annual General Meeting And Dividend Rs.3/- Per Share

      18 Jul 2011
      ex-date
    • split
      ₹2.00

      Face Value Split From Rs.10/- To Rs.2/-

      27 Aug 2010
      ex-date
    • dividend
      ₹13.50

      Annual General Meeting And Dividend Rs.13.50 Per Share

      19 Jul 2010
      ex-date
    • other
      Not available — not reported in this filing

      Agm/Div-Rs.12.50 Pr Share

      20 Jul 2009
      ex-date

    Company announcements

    Company Update
    Announcement under Regulation 30 (LODR)-Change in Management

    Intimation about the Appointment of Senior Management Personnel.

    Company Update
    Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS

    Intimation regarding Grant of 40,157 Stock Options under Lupin Employees Stock Option Scheme 2025.

    Company Update
    Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

    Schedule of Earnings Call for Q2 FY27

    Board MeetingPrice-sensitive
    Board Meeting Intimation for Considering And Approving The Unaudited Standalone And Consolidated Financial Results Of The Company For The Quarter And Half Year Ended September 30, 2026.

    Lupin Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 03/11/2026 ,inter alia, to consider and approve the Unaudited Standalone and Consolidated ....

    Company Update
    Intimation Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015- ESG Rating

    ESG Rating by NSE Sustainability Ratings and Analytics Limited.

    Company Update
    Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

    Certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended on September 30, 2026.

    Company Update
    Announcement under Regulation 30 (LODR)-Press Release / Media Release

    Lupin Receives U.S. FDA Approval for Phytonadione Injectable Emulsion, USP

    Company Update
    Announcement under Regulation 30 (LODR)-Press Release / Media Release

    Lupin Launches Formoflo-G MDI, World's First Fixed-dose Triple Combination Drug for COPD Management.

    Company Update
    Completion Of Buyback Of Shares By Multicare Pharmaceuticals Philippines, Inc.

    Multicare Pharmaceuticals Philippines, Inc. (MPPI) has completed buyback of 30,559 shares, pursuant to which MPPI has become a step-down wholly owned subsidiary of the Company effective ....

    Insider Trading / SAST
    Closure of Trading Window

    Intimation of Closure of Trading Window.

    Company Update
    Announcement under Regulation 30 (LODR)-Press Release / Media Release

    Lupin Receives Tentative Approval from U.S. FDA for Novel Apixaban Oral Suspension.

    Company Update
    Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS

    Intimation of allotment of 24,111 equity shares under ESOP.

    Company Update
    Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

    Intimation about participating in the Analyst/Institutional Investors Meet.

    Company Update
    Announcement under Regulation 30 (LODR)-Press Release / Media Release

    Lupin Receives U.S. FDA Approval for Modafinil Tablets, USP.

    Company Update
    Intimation Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015- ESG Rating

    ESG Rating by Crisil ESG Ratings & Analytics Ltd.

    Filed with BSE (scrip 500257); the last 45 days. Documents open at bseindia.com.

    Documents

    Annual reports

    Earnings calls

    Credit ratings

    Documents open at BSE or the rating agency that issued them.

    Sourced from the company's NSE XBRL filing dated 7 Aug 2026 (unaudited). View the source filing. Figures are as filed and are not investment advice.

    FAQ

    Lupin: common questions

    Answered from the figures on this page.

    Lupin last traded at ₹1,928.90 (NSE, as of 25 Oct 2026). The last session moved it up 0.36%.

    Lupin is valued at about ₹88,207 crore (NSE, as of 25 Oct 2026).

    Lupin trades at a price-to-earnings ratio of 15.98 (NSE, as of 25 Oct 2026). The P/E compares the share price with earnings per share, so it is only comparable between companies in the same industry.

    Lupin has traded between ₹1,892.90 and ₹2,529.50 over the past 52 weeks, to 25 Oct 2026. It is currently 6% of the way up that range.

    Lupin (LUPIN) is classified under Pharma on this site's screener.